Mark G. Lebwohl, MD

Mark Lebwohl, MD, is dean for clinical therapeutics, and chairman emeritus at the Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

Articles by Mark G. Lebwohl, MD

Plaque Psoriasis Case 1: Selecting a Therapeutic Class

ByChristopher G. Bunick, MD, PhD,Mark G. Lebwohl, MD,Jashin Wu, MD,Helen Torok, MD

January 5th 2022

The panel reviews therapeutic classes and their respective benefits in patients being treated for plaque psoriasis.

Plaque Psoriasis Case 1: Patient Counseling and Approaching Therapy

ByChristopher G. Bunick, MD, PhD,Mark G. Lebwohl, MD,Jashin Wu, MD,Helen Torok, MD

January 5th 2022

Centering discussion on a case of plaque psoriasis, experts share their experience with patient counseling and selecting therapy.

Understanding the Psychosocial Burden of Plaque Psoriasis

ByChristopher G. Bunick, MD, PhD,Mark G. Lebwohl, MD,Jashin Wu, MD,Helen Torok, MD

December 23rd 2021

Considerations for the psychological and social impact that plaque psoriasis may have on a patient.

Challenges in Diagnosing Plaque Psoriasis

ByChristopher G. Bunick, MD, PhD,Mark G. Lebwohl, MD,Jashin Wu, MD,Helen Torok, MD

December 23rd 2021

Panelists look deeper into the possible challenges or barriers to making an accurate diagnosis of plaque psoriasis

Identifying Clinical Manifestations of Plaque Psoriasis

ByChristopher G. Bunick, MD, PhD,Mark G. Lebwohl, MD,Jashin Wu, MD,Helen Torok, MD

December 16th 2021

Shared insight on identifying clinical manifestations of plaque psoriasis and making a timely diagnosis.

Pathophysiology of Plaque Psoriasis and Targeted Therapies

ByChristopher G. Bunick, MD, PhD,Mark G. Lebwohl, MD,Helen Torok, MD,Jashin Wu, MD

December 16th 2021

A panel of experts review the nature of plaque psoriasis and the mechanism of action of several classes of targeted therapy.

Use of TNF Inhibitors: The Changing Treatment Paradigm

ByMark G. Lebwohl, MD

August 1st 2003

Current therapies for psoriasis can be very effective and are acceptable to many patients. However, a number of drawbacks associated with these treatments may compromise their effectiveness. Patients undergoing ultraviolet B (UVB) phototherapy or psoralen plus ultraviolet A (PUVA) treatments must keep their appointments 3 times a week to maintain the effectiveness of the therapy.

Mark G. Lebwohl, MD

Articles by Mark G. Lebwohl, MD

Plaque Psoriasis Case 1: Selecting a Therapeutic Class

Plaque Psoriasis Case 1: Patient Counseling and Approaching Therapy

Understanding the Psychosocial Burden of Plaque Psoriasis

Challenges in Diagnosing Plaque Psoriasis

Identifying Clinical Manifestations of Plaque Psoriasis

Pathophysiology of Plaque Psoriasis and Targeted Therapies

Use of TNF Inhibitors: The Changing Treatment Paradigm

Trending on Dermatology Times

Study Suggests Non-Ablative Fractional Laser Reverses Epigenetic Signatures of Skin Aging

Bempikibart Shows Positive Phase 2a Results in Alopecia Areata

The Gut-Skin Axis: New Evidence Links Microbiota to Skin Disease via Inflammatory Cytokines

Social Media Mythbusters: PDRN Serums

Roundtable Discussion Weighs Access and Adherence Challenges in Vitiligo Care